ZA201804414B - Cnp prodrugs with large carrier moieties - Google Patents
Cnp prodrugs with large carrier moietiesInfo
- Publication number
- ZA201804414B ZA201804414B ZA2018/04414A ZA201804414A ZA201804414B ZA 201804414 B ZA201804414 B ZA 201804414B ZA 2018/04414 A ZA2018/04414 A ZA 2018/04414A ZA 201804414 A ZA201804414 A ZA 201804414A ZA 201804414 B ZA201804414 B ZA 201804414B
- Authority
- ZA
- South Africa
- Prior art keywords
- large carrier
- carrier moieties
- cnp prodrugs
- cnp
- prodrugs
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150624 | 2016-01-08 | ||
| EP16179286 | 2016-07-13 | ||
| EP16191458 | 2016-09-29 | ||
| PCT/EP2017/050201 WO2017118693A1 (en) | 2016-01-08 | 2017-01-05 | Cnp prodrugs with large carrier moieties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201804414B true ZA201804414B (en) | 2019-04-24 |
Family
ID=57838356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/04414A ZA201804414B (en) | 2016-01-08 | 2018-07-02 | Cnp prodrugs with large carrier moieties |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10835578B2 (https=) |
| EP (1) | EP3400020A1 (https=) |
| JP (4) | JP7051686B2 (https=) |
| AU (2) | AU2017205268B2 (https=) |
| CA (1) | CA3007976C (https=) |
| MX (1) | MX2018008061A (https=) |
| WO (1) | WO2017118693A1 (https=) |
| ZA (1) | ZA201804414B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| IL297375B2 (en) * | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| HUE062117T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| EP4011396A1 (en) | 2017-03-10 | 2022-06-15 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
| WO2019185705A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
| AU2019340472A1 (en) | 2018-09-12 | 2021-04-01 | Quiapeg Pharmaceuticals Ab | Releasable GLP-1 conjugates |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| MX2022014082A (es) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
| US20230241164A1 (en) * | 2020-06-12 | 2023-08-03 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer |
| CA3236278A1 (en) * | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
| IL316466A (en) * | 2022-05-23 | 2024-12-01 | Ascendis Pharma Growth Disorders As | Liquid pharmaceutical formulations of cnp compounds |
| EP4612167A1 (en) | 2022-11-02 | 2025-09-10 | Novo Nordisk A/S | Cnp compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| AU2003297583B2 (en) | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| MXPA06010782A (es) | 2004-03-23 | 2007-03-28 | Complex Biosystems Gmbh | Ligador de profarmaco. |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| JP2010502231A (ja) | 2006-09-08 | 2010-01-28 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド |
| JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| TWI409081B (zh) | 2006-11-09 | 2013-09-21 | Alcon Res Ltd | 用於藥物輸送之水不溶性聚合物基質 |
| WO2008131179A1 (en) * | 2007-04-20 | 2008-10-30 | Shell Oil Company | In situ heat treatment from multiple layers of a tar sands formation |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| TW201004648A (en) | 2008-05-23 | 2010-02-01 | Enzon Pharmaceuticals Inc | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| ES2608457T3 (es) | 2009-05-20 | 2017-04-11 | Biomarin Pharmaceutical Inc. | Variantes de péptido natriurético de tipo C |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
| EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| MX349950B (es) | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| HK1198913A1 (en) | 2011-08-12 | 2015-06-19 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| JPWO2013161895A1 (ja) | 2012-04-25 | 2015-12-24 | 第一三共株式会社 | 骨修復促進剤 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| KR20160118264A (ko) | 2014-02-27 | 2016-10-11 | 다이이찌 산쿄 가부시키가이샤 | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 |
| CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| EP3242689A1 (en) | 2015-01-09 | 2017-11-15 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
| PL3386531T3 (pl) | 2015-12-08 | 2022-02-28 | Biomarin Pharmaceutical Inc. | Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów |
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| HUE062117T2 (hu) * | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
-
2017
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en not_active Ceased
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP7692454B2/ja active Active
-
2024
- 2024-01-08 US US18/407,324 patent/US20240316153A1/en not_active Abandoned
- 2024-12-19 US US18/986,709 patent/US20250127859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023175776A (ja) | 2023-12-12 |
| WO2017118693A1 (en) | 2017-07-13 |
| US20210177942A1 (en) | 2021-06-17 |
| AU2017205268A1 (en) | 2018-06-07 |
| JP7051686B2 (ja) | 2022-04-11 |
| US20240316153A1 (en) | 2024-09-26 |
| JP2021100937A (ja) | 2021-07-08 |
| JP2022088545A (ja) | 2022-06-14 |
| CA3007976A1 (en) | 2017-07-13 |
| US10835578B2 (en) | 2020-11-17 |
| JP7350123B2 (ja) | 2023-09-25 |
| US20220296682A1 (en) | 2022-09-22 |
| AU2022201416B2 (en) | 2023-06-01 |
| JP7692454B2 (ja) | 2025-06-13 |
| US11154593B2 (en) | 2021-10-26 |
| US20210077584A1 (en) | 2021-03-18 |
| AU2017205268B2 (en) | 2022-02-17 |
| JP6951597B2 (ja) | 2021-10-20 |
| US20250127859A1 (en) | 2025-04-24 |
| AU2022201416A1 (en) | 2022-03-24 |
| US20190015481A1 (en) | 2019-01-17 |
| MX2018008061A (es) | 2018-08-23 |
| CA3007976C (en) | 2023-09-26 |
| EP3400020A1 (en) | 2018-11-14 |
| JP2019507724A (ja) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804414B (en) | Cnp prodrugs with large carrier moieties | |
| IL278970A (en) | CNP drug dispensers | |
| HUS2500009I1 (hu) | PTH prodrugok | |
| IL265588A (en) | Treprostinil prodrugs | |
| ZA201804415B (en) | Cnp prodrugs with carrier attachment at the ring moiety | |
| GB201410549D0 (en) | A carbon article having an improved anti-oxidant coating | |
| ZA201901091B (en) | Briquettes | |
| GB201614100D0 (en) | Carriers | |
| GB201502252D0 (en) | Carrier | |
| PT3215316T (pt) | Artigo abrasivo impresso | |
| IL255516B (en) | Oxabicycloheptane prodrugs | |
| SI3360866T1 (sl) | Mirabegronska predzdravila | |
| GB2531703B (en) | Printed article | |
| GB201509256D0 (en) | Multiple carrier | |
| HU4712U (hu) | Biofilm hordozó | |
| GB2553008B (en) | Camlock | |
| IL246794A0 (en) | Nitrooxy-chromane conjugates that release the group no | |
| HK1262549A1 (en) | Cnp prodrugs with large carrier moieties | |
| GB201708458D0 (en) | Prodrugs | |
| PT3400019T (pt) | Pró-fármacos de cnp com ligação de transportador na unidade de anel | |
| GB2554369B (en) | Contact piece | |
| HK1240818A1 (en) | Cnp prodrugs | |
| GB201601840D0 (en) | Board carrier | |
| GB201709496D0 (en) | Cell activating prodrugs | |
| AP01008S1 (en) | A carrier |